Member Info for Mars1

My guess it was the clinical results from Newcastle Uni going in one direction and the Tranilast data used for regulatory approval in the other. The partner will want to validate the data before paying millions.

Dan in an interview at the end of Feb said data had been exchanged.

Govt guidelines are clear currently you can go to work if it is safe and you can keep 2 metres apart. If you can work from home do so. Pharma is a key industry drugs have to continue to be produced and research is vital. There are 5 staff the lab(s) will separate from the office. Contracts can be worked on at home etc application of common sense. Pharma companies were given the covid code so whether they are checking inventory to see if there is anything in stock is then debatable.

Background for NXP002 https://m.youtube.com/watch?v=rRccHplXSDY

There are many reasons why NXP002 is needed
https://www.google.co.uk/amp/s/www.express.co.uk/life-style/health/1120977/pulmonary-fibrosis-lung-disease-clare-beckett-nhs/amp

One other development will occur when news is released. Any contract with a Japanese firm will be plastered over the Asian continent internet as occurred with Kissei last deal. NFX will become known to investors round the world. What will happen then?!

This is also of interest Kissei have already licensed deals on Tranilast in the past in 2007 with a US firm in respect of MS
https://www.kissei.co.jp/e_contents/news/2007/20070723-691.html

Soup unlikely an IPF version of Tranilast will not be taken up here is the brand useage of the drug already for asthma
Brand Names
Ao Te Min
Bu Chang Pharm, China
Arenist 0.5%
Toa Yakuhin, Japan
Brecrus
Towa Yakuhin, Japan
Brecrus 10%
Towa Yakuhin, Japan
Hustigen
Koa Isei, Japan
Krix
Joongwae Shinyak, South Korea
Rizaben
Kissei Pharmaceutical, Japan
Rizaben 0.5%
Kissei Pharmaceutical, Japan
Rizaben 10%
Kissei Pharmaceutical, Japan
Rizaben 5%
Kissei Pharmaceutical, Japan
Shun Qi [+ Salbutamol]
Sanyu Pharmaceutical, China
Tramelas 0.5%
Nitten Pharmaceutical, Japan
Tramelas PF 0.5%
Nippon Tenganyaku Kenkyujo, Japan
Tranilast
Choseido Pharmaceutical, Japan; Takeda Teva Pharma, Japan
Tranilast 0.5%
Fujifilm Pharma, Japan; Nihon Generic, Japan; Sawai Seiyaku, Japan; Shionogi Seiyaku, Japan; Teika Seiyaku, Japan
Tranilast DS 5%
Choseido Pharmaceutical, Japan
Tranilast NEGPF
Northeast General Pharmaceutical Factory NEGPF, China

Yes we have had the one share buy usual RNS warning but then followed by big buys could support the code

Bit of background reading on USTC the premier research school in China
http://en.ustc.edu.cn/2020/0310/c15527a414285/page.htm

Without doubt Japan is interested in IPF, as seen with Shionogi’s phase 1 interest. Also when Kissei was selling Tranilast under IP the number of Japanese firms in breach of patent was surprising. We are a day closer every day to a deal. If the deal is anything like CG Oncology this sp will not hang around. For the doubters apologies a little stir crazy but a lot better off than some.

Dan in Sept confirmed he was in discussions with more than one company for NXP002. Since then there has been a preferred partner. Silence does not mean failure confidentiality is important and there are more choices. In the December podcast Dan confirmed the partners had agreed the inhaling route and in February he said the deal is transformational (so terms known) and data had been exchanged. He also said to date everything had been done without the need to travel. So up to the last podcast the partner had not required face to face clarification or needed to interrogate the results. Patience required.
RNS 3/12/18
·    Data demonstrates NXP002 candidates strongly inhibit fibrosis ex-vivo, even in very severely fibrotic patient tissue, giving strong support for treating IPF and other fibrotic lung conditions
·     In addition, NXP002 demonstrated specific action measured against key inflammatory targets
·     NXP002 out-performed current standard of care treatment, Esbriet ® (pirfenidon)
RNS 25/10/19
It confirms that the Company is in discussion with multiple potential licensees in Japan and Asia, including but not limited to its NXP002 programme.
RNS 25/11
Nuformix is putting in place the team and development partnerships to pursue this path for NXP002. Funds from the Placing will allow Nuformix to drive progress in this programme and support Nuformix's position in the Group's on-going discussions with multiple potential development partners in Asia and the US.
RNS 24/12
·     NXP002 progression towards clinic
o  Partnerships in place to support development of NXP002 as an inhaled therapy for Idiopathic Pulmonary Fibrosis ("IPF") and IPF-induced cough
o  Discussions with development partners commenced
o  Assembling expert team to progress to patient studies

Shows deals are now been completed surely will just be waiting for clinical due diligence on exchanges data

Just realised a $30m investment similar to CG, Kissei could buy the company they have not got through phase 3.

Cannot afford another leak it sounded from a comment from Dan in one of the podcasts the Times October leak did negotiations no favours.

Imagine the impact on the sp if the partner decides to invest in the equity could be a quick share swap with CPI.

Have just entered a new licensing agreement announced today with CG Oncology terms as follows; Under the terms of this agreement, we will make a $30 million equity investment in CG and pay a $10 million licensing fee after initiation of Phase III clinical trials in the United States. In addition, we will pay CG up to $100 million in development and commercial milestone payments, as well as certain royalties on sales in our territory.
https://www.kissei.co.jp/e_contents/news/2020/20200327-3561.html

Is very subjective, one poster saying no value if no deals. Value of course is what the market determines by supply and demand and we have one ruthless seller as a result substantially undervalues the company. It takes $1bn to develop a new drug therefore ‘value’ to a big pharma is different to market value. So what would a big pharma pay for 2 oncology, 1 fibrosis drugs and IP in cannabinoids. As their concept of proof evolves marketability will rapidly rise anything below development cost for a big pharma has to be a win. If we take NXP002 alone for Japan I struggle with the numbers as they are hard to fathom logically. Japan has about 10% of the market of £5BN but a growing ageing population. If the market is £500m and NXP obtain 20% royalties it is annual income of £100m at a pe of 20 for quality low cost income values £2bn for one small part of the business. As I say difficult to fathom. Either way the future is bright.

Sorry Esbriet is Genentech see attached for
Comparison with Ofev
https://pulmonaryfibrosisnews.com/2019/04/23/many-ipf-patients-switching-from-esbriet-to-ofev-discontinue-treatment/
Both have reported side effects

This is Ofev (nintedanib) which is one of two drugs currently used for IPF both of which is reported to have side effects. This is provided by a US company Genentech and it is claimed to be not as good as Esbriet. In the clinical trials 002 outperformed Esbriet.